| Compound |
Cell Lines – IC50 mM ± S.E.M |
Primary culture |
| |
HL-60 |
SF-295 |
HCT-8 |
Human
Lymphocytes |
2a
(LASSBio-1599) |
> 300 |
208.67 ±7.28 |
173.41 ±5.91 |
194.3 ±2.17 |
2b
(LASSBio-1598) |
> 300 |
287.53 ±3.15 |
> 300 |
> 300 |
2c
(LASSBio-1597) |
74.40 ±9.80 |
107.64 ±5.10 |
39.61 ±7.05 |
> 300 |
6
(LASSBio-1724) |
> 300 |
> 300 |
> 300 |
> 300 |
7
(LASSBio-1725) |
> 300 |
> 300 |
> 300 |
> 300 |
8
(LASSBio-1726) |
> 300 |
> 300 |
> 300 |
> 300 |
9
(LASSBio-1723) |
> 300 |
> 300 |
> 300 |
> 300 |
10
(LASSBio-1727) |
35.75 ±2.51 |
> 300 |
> 300 |
> 300 |
| Imatinib |
22.81 ±3.11 |
41.53 ±5.73 |
34.03 ±4.11 |
> 300 |
| Doxorubicin |
0.04 ±0.01 |
0.48 ±0.02 |
0.02 ±0.01 |
0.37 ±0.01 |
|
| HL-60 (human leukemia); SF-295 (human glioblastoma); HCT-8 (human colorectal carcinoma) |
| Table 2: Antiproliferative activity of carboxamides 2a-c, imatinib and doxorubicin (positive control) against HL-60, SF-295, HCT-8 tumor cell lines and their cytotoxic activity against primary culture of human lymphocytes. |